Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 28, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial statements or performance metrics.
Material Changes
The only material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On January 27, 2005, Abacus (GSK) Trustees Limited transferred 3,263 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe—hold an interest in the shares held by the trust in the same capacity as other employees. No other risks, contingencies, or outlook guidance are provided in this text.
Key Facts for Investor Verification
- 3,263 Ordinary Shares were transferred from the GSK Trust to employee plan participants on January 27, 2005.
- Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe have an indirect interest in the trust's holdings.
- This filing contains no financial performance data for the period.